2021 Clinical Development FDA Approval RNA 
Metabolite Tales Blog
JANUARY 26, 2023
Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism. References Iversen et al.,
Drug Discovery World
MARCH 7, 2023
Dr Natalie Kenny, Founder and CEO, BioGrad In 2021, Dr Kenny won EVA’s Businesswoman of the Year award, The Business Desk top 50 City Region Leader for Liverpool and The Business Desk’s North West Investment Award. She was appointed as CEO of Novo Nordisk Pharmatech in 2021. She has published over 30 peer-reviewed papers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 2, 2024
OECD data places Switzerland second in the world for biotechnology R&D intensity 1 , and in 2021, the country had the seventh largest share of the global biotech market 2. In 2005, Glycart was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED).
The Pharma Data
JULY 29, 2021
econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We Second Quarter 2021 Financial Results. Total second quarter 2021 revenue of $6.2 As of June 30, 2021, Gilead had $7.4
The Pharma Data
JANUARY 31, 2021
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”
The Pharma Data
DECEMBER 8, 2020
Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. BioAge is on the cusp of taking pilot therapies BGE-117 and BGE-175 into clinical trials, targeting the first half of 2021.
The Pharma Data
DECEMBER 3, 2020
Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines. The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
Expert insights. Personalized for you.
52 
Let's personalize your content